Forscher haben einen Bluttest entwickelt, der Bauchspeicheldrüsenkrebs, eine der tödlichsten Krebsarten, im Frühstadium erkennen kann. Der neue Test könnte die Überlebensraten bei Bauchspeicheldrüsenkrebs verbessern, der tendenziell in späten Stadien diagnostiziert wird, in denen die Wahrscheinlichkeit einer wirksamen Therapie geringer ist

>In the study, scientists at the University of Pennsylvania Perelman School of Medicine, Philadelphia, and Mayo Clinic, Rochester, Minnesota, used a phased approach to testing biomarkers in the blood collected from patients with pancreatic cancer and similar patients without the malignancy. They included two blood biomarkers previously explored for use in this way, carbohydrate antigen 19-9 (CA19-9), which is used to monitor treatment response in patients with pancreatic cancer, and thrombospondin 2 (THBS2), another previously used marker. Neither worked well as a screening tool. CA19-9 can be elevated in people with benign conditions such as pancreatitis and bile duct obstruction while other patients don’t produce it at all due to genetic factors.
>
>In analyzing banked blood samples, the team found two novel biomarker proteins that were elevated in the blood of early-stage pancreatic cancer patients compared with healthy volunteers, aminopeptidase N (ANPEP) and polymeric immunoglobin receptor (PIGR).
>
>When they combined ANPEP and PIGR with CA19-9 and THBS2 the four-marker panel successfully distinguished pancreatic cancer cases from non-cases 91.9% of the time for all stages combined at a false positive rate of 5% in non-cases. Similarly, for early-stage (stage I/II) cancer, the four-marker test identified 87.5% of cases.
>
>“By adding ANPEP and PIGR to the existing markers, we’ve significantly improved our ability to detect this cancer when it’s most treatable,” said the study’s lead investigator, Kenneth Zaret, Ph.D., University of Pennsylvania’s Perelman School of Medicine.
>
>Importantly, the four-marker test successfully distinguished cancer patients from both healthy individuals and those with non-cancerous pancreatic conditions, such as pancreatitis.

[Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor (PIGR) | Clinical Cancer Research | American Association for Cancer Research](https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-25-3297/771953/Improving-a-Plasma-Biomarker-Panel-for-Early?redirectedFrom=fulltext)